These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 34981829)

  • 41. Three-year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: results from the randomized phase 3 CIMPACT trial.
    Warren RB; Lebwohl M; Sofen H; Piguet V; Augustin M; Brock F; C Arendt ; Fierens F; Blauvelt A
    J Eur Acad Dermatol Venereol; 2021 Dec; 35(12):2398-2408. PubMed ID: 34192387
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Secukinumab demonstrates superiority over narrow-band ultraviolet B phototherapy in new-onset moderate to severe plaque psoriasis patients: Week 52 results from the STEPIn study.
    Iversen L; Conrad C; Eidsmo L; Costanzo A; Narbutt J; Pinter A; Kingo K; Rivera Diaz R; Kolbinger F; Nanna M; Frueh JA; Jagiello P
    J Eur Acad Dermatol Venereol; 2023 May; 37(5):1004-1016. PubMed ID: 36606536
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and Safety of Certolizumab Pegol in Japanese Patients with Moderate to Severe Plaque Psoriasis: 52-Week Results.
    Umezawa Y; Asahina A; Imafuku S; Tada Y; Sano S; Morita A; Sakurai S; Hoshii N; Tilt N; Nakagawa H
    Dermatol Ther (Heidelb); 2021 Jun; 11(3):943-960. PubMed ID: 33886085
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Secukinumab Self-Administration by Prefilled Syringe Maintains Reduction of Plaque Psoriasis Severity Over 52 Weeks: Results of the FEATURE Trial.
    Gottlieb AB; Blauvelt A; Prinz JC; Papanastasiou P; Pathan R; Nyirady J; Fox T; Papavassilis C
    J Drugs Dermatol; 2016 Oct; 15(10):1226-1234. PubMed ID: 27741340
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term efficacy and safety of secukinumab in Japanese patients with moderate to severe plaque psoriasis: 3-year results of a double-blind extension study.
    Okubo Y; Ohtsuki M; Morita A; Yamaguchi M; Shima T; Tani Y; Nakagawa H;
    J Dermatol; 2019 Mar; 46(3):186-192. PubMed ID: 30672623
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy of secukinumab without the initial weekly loading dose in patients with chronic plaque psoriasis.
    Gisondi P; Rovaris M; Piaserico S; Girolomoni G
    Br J Dermatol; 2020 Jan; 182(1):175-179. PubMed ID: 31004509
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies.
    Gottlieb AB; Lacour JP; Korman N; Wilhelm S; Dutronc Y; Schacht A; Erickson J; Zhang L; Mallbris L; Gerdes S
    J Eur Acad Dermatol Venereol; 2017 Apr; 31(4):679-685. PubMed ID: 27696577
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER-3 study.
    Lebwohl MG; Gordon KB; Gallo G; Zhang L; Paul C
    J Eur Acad Dermatol Venereol; 2020 Feb; 34(2):301-309. PubMed ID: 31479549
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE).
    Thaçi D; Humeniuk J; Frambach Y; Bissonnette R; Goodman JJ; Shevade S; Gong Y; Papavassilis C;
    Br J Dermatol; 2015 Sep; 173(3):777-87. PubMed ID: 25823958
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Secukinumab demonstrates superior efficacy and a faster response in clearing skin in Asian subjects with moderate to severe plaque psoriasis compared with ustekinumab: Subgroup analysis from the CLEAR study.
    Lee MG; Huang YH; Lee JH; Lee SC; Kim TG; Aw DC; Bao W; Dee CMA; Guana A; Tsai TF
    J Dermatol; 2019 Sep; 46(9):752-758. PubMed ID: 31342560
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term efficacy, safety and tolerability of secukinumab in children and adolescents with severe chronic plaque psoriasis: Two-year results from a Phase III double-blind, randomized controlled trial.
    Krasowska D; Gambichler T; Cortés C; Horev A; Compagno N; Dahale SS; Papanastasiou P; Keefe D
    J Eur Acad Dermatol Venereol; 2023 Mar; ():. PubMed ID: 36971771
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study).
    Bissonnette R; Luger T; Thaçi D; Toth D; Lacombe A; Xia S; Mazur R; Patekar M; Charef P; Milutinovic M; Leonardi C; Mrowietz U
    J Eur Acad Dermatol Venereol; 2018 Sep; 32(9):1507-1514. PubMed ID: 29444376
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE).
    Mrowietz U; Leonardi CL; Girolomoni G; Toth D; Morita A; Balki SA; Szepietowski JC; Regnault P; Thurston H; Papavassilis C;
    J Am Acad Dermatol; 2015 Jul; 73(1):27-36.e1. PubMed ID: 25982539
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sustained efficacy of secukinumab in patients with moderate-to-severe palmoplantar psoriasis: 2·5-year results from GESTURE, a randomized, double-blind, placebo-controlled trial.
    Gottlieb AB; Kubanov A; van Doorn M; Sullivan J; Papp KA; You R; Regnault P; Frueh JA
    Br J Dermatol; 2020 Apr; 182(4):889-899. PubMed ID: 31286480
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and Safety of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis and Skin of Color: Results from the Pooled AMAGINE-2/-3 Randomized Trials.
    McMichael A; Desai SR; Qureshi A; Rastogi S; Alexis AF
    Am J Clin Dermatol; 2019 Apr; 20(2):267-276. PubMed ID: 30471012
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.
    Reich K; Papp KA; Blauvelt A; Langley RG; Armstrong A; Warren RB; Gordon KB; Merola JF; Okubo Y; Madden C; Wang M; Cioffi C; Vanvoorden V; Lebwohl M
    Lancet; 2021 Feb; 397(10273):487-498. PubMed ID: 33549193
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany.
    Augustin M; McBride D; Gilloteau I; O'Neill C; Neidhardt K; Graham CN
    J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2191-2199. PubMed ID: 29729105
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Secukinumab in plaque psoriasis--results of two phase 3 trials.
    Langley RG; Elewski BE; Lebwohl M; Reich K; Griffiths CE; Papp K; Puig L; Nakagawa H; Spelman L; Sigurgeirsson B; Rivas E; Tsai TF; Wasel N; Tyring S; Salko T; Hampele I; Notter M; Karpov A; Helou S; Papavassilis C; ;
    N Engl J Med; 2014 Jul; 371(4):326-38. PubMed ID: 25007392
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse).
    Stein Gold LF; Bagel J; Tyring SK; Hong HC; Pavlovsky L; Vender R; Pinter A; Reich A; Drogaris L; Wu T; Patel M; Soliman AM; Photowala H; Stakias V; Richter S; Papp KA
    Br J Dermatol; 2023 Oct; 189(5):540-552. PubMed ID: 37488811
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Secukinumab efficacy and safety in indian patients with moderate-to-severe plaque psoriasis: Sub-analysis from FIXTURE, a randomized, placebo-controlled, phase 3 study.
    Bhat RM; Leelavathy B; Aradhya SS; Gopal MG; Pratap DV; Mubashir M; Srinivas P; Pande SY; Thavkar AS
    Indian Dermatol Online J; 2017; 8(1):16-24. PubMed ID: 28217466
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.